Hims’ stock fell more than 23% by Friday afternoon, wiping out gains earlier this week after the company announced plans to roll out at-home blood testing over the next year. Shares of Eli Lilly and ...
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...
The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...
Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.They cost so much partly because of ...
Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...
Eli Lilly and Co. shares climbed about 2% Thursday morning to $857.40 while broader trading indexes started the day mixed. Lilly's stock has already climbed 9% so far this year, as of Wednesday.
(This Aug.15 story corrects to fix spelling of name in paragraph 17) By Deena Beasley (Reuters) - Drugmakers are launching new medicines at record-high prices this year, a Reuters ...
David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; Chief ...